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Abstract
The anti-inflammatory properties of glucocorticoids are well known but their protective effects exerted with a low potency
against heavy metals-induced pulmonary inflammation remain unclear. In this study, a model of acute pulmonary
inflammation induced by a single inhalation of cadmium in male Sprague-Dawley rats was used to investigate whether
formoterol can improve the anti-inflammatory effects of budesonide. The cadmium-related inflammatory responses,
including matrix metalloproteinase-9 (MMP-9) activity, were evaluated. Compared to the values obtained in rats exposed to
cadmium, pretreatment of inhaled budesonide (0.5 mg/15 ml) elicited a significant decrease in total cell and neutrophil
counts in bronchoalveolar lavage fluid (BALF) associated with a significant reduction of MMP-9 activity which was highly
correlated with the number of inflammatory cells in BALF. Additionally, cadmium-induced lung injuries characterized by
inflammatory cell infiltration within alveoli and the interstitium were attenuated by the pre-treatment of budesonide.
Though the low concentration of budesonide (0.25 mg/15 ml) exerted a very limited inhibitory effects in the present rat
model, its combination with an inefficient concentration of formoterol (0.5 mg/30 ml) showed an enhanced inhibitory
effect on neutrophil and total cell counts as well as on the histological lung injuries associated with a potentiation of
inhibition on the MMP-9 activity. In conclusion, high concentration of budesonide alone could partially protect the lungs
against cadmium exposure induced-acute neutrophilic pulmonary inflammation via the inhibition of MMP-9 activity. The
combination with formoterol could enhance the protective effects of both drugs, suggesting a new therapeutic strategy for
the treatment of heavy metals-induced lung diseases.
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Introduction
Cadmium is listed by the Agency for Toxic Substances and
Disease Registry as the world’s seventh largest hazardous
substance. It is also classified as a Group 1 carcinogen by
International Agency for Research on Cancer (IARC) [1].
Inhalation is an important route of cadmium exposure for
occupationally and non-occupationally exposed population. In-
deed, tobacco smoke can be an important vector for cadmium in
smokers but also in passive smokers due to the high concentrations
that can be reached in indoor air [2]. Cadmium is also widely used
in some industries and the majority of cadmium present in
atmosphere is the result of fossil fuel combustion and municipal
waste incineration [3]. Lungs thus became a toxicological target as
illustrated by the marked deficit in lung function correlated with
an increase in urinary cadmium concentration which has been
found in workers exposed to cadmium in jewelry workshops [4].
The involvement of cadmium in obstructive lung diseases (OLD),
including chronic obstructive pulmonary disease (COPD), is also
supported by several studies in human, animal models and cell
cultures illustrating the deleterious effects of this heavy metal and
mechanisms of action on pulmonary tissue [5–8]. Acute exposure
to cadmium also induces deterioration in lung function and
neutrophilic infiltration which is a dominant component of COPD
especially during acute exacerbations of this chronic inflammatory
process [9].
Experimental models mimicking the pathological characteristics
of these inflammatory diseases and allowing pharmacological
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e109136
research about inhaled cadmium-induced acute and chronic
pulmonary inflammation have been developed in rats [10–12].
As in naturally occurring diseases, matrix metalloproteinases
(MMPs) play an important role in rats, especially MMP-9
produced by resident and inflammatory cells, especially macro-
phages [12–15]. Inhibition of these enzymes provides a very
effective protective effect against lung injuries especially against
cadmium-induced neutrophils migration [11,16,17]. Likewise in
patients with COPD, this neutrophilic inflammation appears
rather poorly sensitive to the action of glucocorticoids (GCs)
nevertheless recognized as the most powerful anti-inflammatory
agents to treat inflammatory diseases as asthma [18,19]. The
absence of influence of GCs on MMPs activity has been suggested
to be partially responsible of this lack of efficacy [20] but their
action on pulmonary MMPs activity especially in relation with
heavy metals inhalation remains controversial and further studies
are necessary to investigate how to improve their anti-inflamma-
tory effects [19,21,22].
Recovery of these anti-inflammatory effects is a key therapeutic
challenge [23,24]. The anti-inflammatory effects of b2-adrenergic
receptor agonists, classically used as bronchodilators, have been
recently reviewed and previously demonstrated in rats exposed to
cadmium [11,12,25]. Clinical benefits provided by the combina-
tion of long acting b2-adrenergic receptor agonists (LABAs) with
GCs have been reported in diseases as asthma and sometimes in
COPD [26–29] as well as in vitro [30–32]. However, nothing is
known about this interaction and the possible role played by
MMPs in refractory models of lung inflammation induced by
heavy metals [30,31,33].
By using the rat model of acute pulmonary inflammation
associated with an elevated MMP-9 activity induced by a single
inhalation of cadmium, the aim of this study was to determine
whether inefficient concentrations of inhaled budesonide, alone or
in combination with formoterol, can exert a protective effect
against cadmium-induced acute pulmonary inflammation in rats.
We also examined whether the expected anti-inflammatory effects
of budesonide and/or formoterol were associated with a modu-
lation of MMP-9 activity.
Materials and Methods
Ethics Statement
Male Sprague-Dawley rats (n = 84) weighing 250–300 g from
Shanghai SLAC Laboratory Animal Co. Ltd. were used. All
experimental procedures were conducted in accordance with the
guidelines for the care and use of laboratory animals from the
Experimental Animal Care and Use Committee of Shanghai Jiao
Tong University. Animals were housed in the animal facility of the
laboratory with a 12:12 h light-dark cycle at a constant ambient
temperature (2362uC) and humidity (60%65%), with free access
to water and food, for at least 24 h before experimentation. All
efforts were made to minimize suffering. All experimental
protocols were approved by the Experimental Animal Care and
Use Committee of Shanghai Jiao Tong University School of
Medicine.
Animals were placed in an exposure chamber (length6width6
height: 50 cm650 cm637 cm) to be exposed to drugs and
cadmium by an ultrasonic nebulizer (402AI, YuYue Medical
Equipment Co., Ltd. Jiangsu, China) known to generate particles
of diameter ranging 1–5 mm. The aerosol output was 3 ml/min
which was propelled by the airflow of 30 L/min into the chamber.
The animals were allowed to move freely during exposure. Two
lateral opening 10 mm in diameter in the chamber ensured a
regular dispersion of the aerosol. The whole system was placed
within an extractor hood ensuring a safe aerosol evacuation. The
animals were sacrificed 24 h later by a lethal intraperitoneal
injection of pentobarbital (200 mg/kg), a time corresponding to
the maximum inflammatory response induced by cadmium. The
lungs were removed from the chest. As described previously [10],
bronchoalveolar lavage fluid (BALF) was collected by flushing
8 ml of saline two times successively in the right lung through a
cannula located in the main bronchus. BALF recovery ranged
from 80 to 90% and did not differ between groups of animals. The
liquid was then collected for subsequent BALF analysis. The left
lung tissue was fixed for histological examination.
Agents and dose selection
Cadmium chloride, formoterol fumarate and budesonide were
obtained from Sigma (St Louis, USA). Cadmium chloride was
prepared in saline to get a 0.1% solution. Formoterol fumarate
and budesonide were first dissolved in DMSO and then in saline to
get a 0.1% DMSO in saline solution. Two different concentrations
of formoterol (0.5 mg/30 ml, 1 mg/30 ml of nebulized solution)
have been selected according to our previous study demonstrating
the bronchodilating effects and anti-inflammatory properties of
this drug [11]. The aim of the study being to check whether low
doses of glucocorticoids can interact with formoterol to better
control the cadmium-induced pulmonary inflammation, only two
doses were assessed. The doses of budesonide have been
determined during preliminary assays demonstrating the anti-
inflammatory effects of this agent in rats exposed during 1 h to
cadmium. Two doses of budesonide (0.25 mg/15 ml, 0.5 mg/
15 ml of nebulized solution) inducing mild to moderate anti-
inflammatory effects were selected in the present study.
Study design and experimental protocols
Animals were pretreated with formoterol, budesonide or a
combination of both drugs (0.5 mg/30 ml of formoterol combined
with 0.25 mg/15 ml of budesonide) before the cadmium (5
groups, n = 6 per group) or saline (5 groups, n = 6 per group)
exposure. Formoterol (30 ml) and budesonide (15 ml) solutions
were nebulized at the same rate during 15 and 10 min
respectively. When combined, formoterol was first nebulized
immediately followed by budesonide. Three corresponding
cadmium-exposed control groups were also investigated. Before
inhalation of the cadmium solution, animals of these groups were
exposed to nebulized solution (0.1% DMSO solution of 0.9%
NaCl) during 15 min (n= 6), 10 min (n= 6) or 25 min (n= 6). As
the duration of the pretreatment period with the vehicle had no
influence on the response to the cadmium, all data from the
cadmium-exposed animals were pooled to obtain a single
cadmium control group.
Finally a sham group (n= 6) underwent the same protocol for
85 min with the corresponding vehicles (25 min with 0.1%
DMSO in 0.9% NaCl solution) followed by a saline inhalation
for 60 min.
Cytological analysis in bronchoalveolar lavage fluid
(BALF)
BALF was centrifuged for 15 min at 4uC (450 g) and the
supernatant was fractioned into 1 ml samples, which were kept at
280uC for further analysis. A total cell count was performed using
a Thomas cell. 150 ml of BALF was used for differential cell count
by cytospin centrifugation and May Gru¨nwald Giemsa staining.
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Determination of matrix metalloproteinase activity in
BALF
The activity of MMP-9 was detected by gelatin zymography as
previously described [10]. Briefly, 10 ml of supernatant of BALF
was added to Laemmli buffer at a 1:1 ratio. The samples were
subjected to electrophoresis on 10% acrylamide SDS gels
containing porcine skin gelatine (1%, Sigma, St. Louis, USA).
After loading onto gelatin gels with standards, the gels were then
washed twice in Triton X-100 2% for 30 min followed by an
incubation at 37uC overnight. After staining with Coomassie blue
and destaining, gelatinolytic activity appeared as unstained zones
against a blue background. Quantification of MMP activity was
analyzed with Image J (Image Processing and Analysis in Java).
Results were expressed as average arbitrary units (AU) corre-
sponding to pixel density6mm2 for the bands of proteolysis
normalized by the same value calculated for a known amounts of
standard (human proenzyme MMP-9, San Diego, CA, USA). As
the latent and active bands were so close that it was difficult to
accurately analyze these two forms of MMPs respectively, the
latent and active bands were taken together for analysis. In the
sham group, MMP-9 activity was sometimes undetectable. So a 0
value was attributed to the corresponding samples.
Detection of cytokines and chemokines in BALF
The levels of IL-1b, TNF-a and IL-8 in BALF were analyzed by
ELISA according to the manufacturer’s instruction (Rapidbio Lab,
California, USA).
Lung histological examination
The left lung was harvested and fixed in 10% phosphate
buffered formalin. After 24 h of fixation, the median portion was
cut and embedded in paraffin. The paraffin block per lung was cut
into 2–3 mm transversal slices and stained with hematoxylin and
eosin (H&E). Three nonoverlapping slices from each lung sample
Figure 1. Protective effects of formoterol and budesonide on the concentrations of total cells (A), neutrophils (B) and macrophages
(C) in bronchoalveolar lavage fluid in rats exposed to cadmium. CdCl2: 0.1% CdCl2 cadmium group; FMT 0.5+Cd and FMT 1+Cd: animals
pretreated with increasing concentrations of formoterol (0.5 mg/30 ml; 1 mg/30 ml respectively) before cadmium inhalation; BUD 0.25+Cd and BUD
0.5+Cd: animals exposed to budesonide (0.25 mg/15 ml and 0.5 mg/15 ml respectively) followed by cadmium exposure; * Indicates a significant
difference in comparison with sham group (* P,0.05, ** P,0.01, *** P,0.001); # indicates a significant difference in comparison with cadmium-
exposed group (# P,0.05, ## P,0.01, ###P,0.001).
doi:10.1371/journal.pone.0109136.g001
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were randomly screened. Care was taken to avoid regions
containing pleura or large bronchi. Slices were examined by a
pathologist blinded to sample groups. The degree of microscopic
lung injuries was analyzed using a semi quantitative method. Four
fields per slice were randomly selected and evaluated for several
variables (neutrophil and macrophage infiltration, edema and
hemorrhage) according to severity and extent of inflammatory
responses, and relative scores were attributed. The mean of three
slices per lung was taken as representative value of each animal.
For each slice, the extent of injury was assigned a score of 0 (injury
less than 5% of the field), 1 (5–20% of the field), 2 (20%–40%), or
3 (.40%), and the severity was graded as 0 (normal, no cellular
infiltration), 1 (mild injury, scarcely neutrophil or macrophage
infiltration), 2 (moderate injury, moderate neutrophil or macro-
phage infiltration with mild edema or hemorrhage), or 3 (severe
injury, severe inflammatory infiltration with moderate edema or
hemorrhage). The extent and the severity score were expressed
respectively by mean 6 SD of every group.
Statistical analysis of results
All data were normally distributed and presented as means 6
S.D., and were analyzed by one-way analysis of variance
(ANOVA) by using graphpad prism 5.0 (Graphpad Software.
San Diego, CA). Student-Newman-Keuls tests were performed
subsequently for comparison between groups. The correlation
analysis was performed by linear regression and the value r was
measured as coefficient of correlation. P,0.05 was considered as
statistically significant.
Results
Effects of formoterol and/or budesonide on differential
BALF cell counts
A single cadmium exposure induced a significant increase in
total cell number in BALF which was attributed to a marked
increase in neutrophil and macrophage concentrations in BALF
(Fig. 1A–C). Pretreatment of healthy rats with formoterol and/or
budesonide had no effect on BALF cell counts as compared to
sham group (data not shown).
Though the low concentration of formoterol (0.5 mg/30 ml)
had no inhibitory effect on the differential cell counts in BALF, the
high concentration of formoterol (1 mg/30 ml) induced a signif-
icant decrease in the concentrations of both total cells and
neutrophils in BALF while the macrophage concentration was not
Figure 2. Effects of formoterol in combination with budesonide on the concentrations of total cells (A), neutrophils (B) and
macrophages (C) in bronchoalveolar lavage fluid in rats exposed to cadmium. FMT 0.5+BUD 0.25+Cd: group pretreated with a
combination of 0.5 mg/30 ml formoterol and 0.25 mg/15 ml budesonide before cadmium. For other abbreviation meaning: see Fig. 1 legend. *
Indicates a significant difference in comparison with sham group (* P,0.05, ** P,0.01, *** P,0.001); # indicates a significant difference in
comparison with cadmium-exposed group (# P,0.05, ## P,0.01, ###P,0.001); 1 indicates a significant difference in comparison with FMT 0.5+
BUD 0.25+Cd group (1 P,0.05, 11 P,0.01).
doi:10.1371/journal.pone.0109136.g002
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affected (Fig. 1A–C). Pretreatment with the high concentration of
budesonide (0.5 mg/15 ml) caused a significant decrease in the
concentrations of total cells, neutrophils and macrophages in
BALF. However, only the concentration of neutrophils in BALF
was reduced by the low concentration of budesonide (0.25 mg/
15 ml) (Fig. 1A–C).
A marked and very significant reduction of total inflammatory
cell counts in BALF was observed when the low concentrations of
formoterol and budesonide were combined. The inhibitory effect
of the low concentration of budesonide on the number of
neutrophils was significantly amplified when this drug was
combined with the low inefficient concentration of formoterol
(Fig. 2A–B). Though the combination did not induce any
significant decrease in macrophage count compared to the animals
exposed to cadmium, this parameter was no more significantly
different when compared with the sham group (Fig. 2C).
Effects of formoterol and/or budesonide on lung injuries
evaluated by light microscopy and lung
histomorphometry
Concerning the histological examination, the lung architecture
was preserved in sham group, with intact parenchyma and
absence of inflammatory injury. Marked pathological changes in
the peribronchiolar regions and throughout the alveoli, charac-
terized by neutrophil and macrophage infiltration within alveoli
and pulmonary parenchyma were observed. Focal congestion and
hemorrhage were also sometimes observed in some portions of the
cadmium-exposed lungs. Figure 3A and 3B shows representative
lung tissue from rats exposed respectively to saline or cadmium.
As demonstrated by the significant decrease in the scores
attributed to the extent and severity of inflammatory cell
infiltration, a significant reduction of histological lung injuries,
especially neutrophil and macrophage infiltration within alveoli,
were observed in rats pretreated with the high concentration of
formoterol (Fig. 4A–B). However, only a reduced extent of
inflammatory injuries was detected in rats pretreated with the
low concentration of formoterol while the severity was not
statistically affected by this pretreatment (Fig. 3C, Fig. 4A–B).
Similar dose-dependent effects on lung injuries were observed in
rats pretreated with different concentrations of budesonide. The
low concentration of budesonide did not diminish the cadmium-
induced lung injuries, except a decrease of the mean score
attributed to the extent of inflammatory cell infiltration (Fig. 3D,
Fig. 4A–B). As indicated by the inflammatory scores of severity
and extent, the high concentration of budesonide significantly
diminished the neutrophilic infiltration within the alveoli and in
alveolar interstitium (Fig. 4A–B). The combination of both agents
at low concentrations markedly protected the lungs against the
inflammatory effects of cadmium (Fig. 3E). While both drugs were
without effect on the severity of lung injuries when inhaled at low
concentrations, this parameter was significantly reduced when
animals were pretreated with the combination indicating a
potentiated action on this key parameter (Fig. 4C). The extent of
inflammation was no longer significantly different from that of the
sham group (Fig. 4D).
Effect of formoterol and/or budesonide on MMP-9
activity in BALF
A significant increase in MMP-9 gelatinolytic activity was
detected in BALF after a single exposure of cadmium, while its
activity was very low and even undectable in the sham group
(Fig. 5A). Neither formoterol nor budesonide exerted any signif-
icant influence on MMP-9 activity in healthy rats (data not
shown).
As shown in figure 5A, pretreatment with the high concentra-
tions of formoterol and budesonide resulted in a marked decrease
in MMP-9 activity while the low concentrations of both drugs
failed to prevent the cadmium-induced increase in MMP-9
Figure 3. Effects of pretreatment with formoterol and/or budesonide on the histological injuries induced by cadmium inhalation.
Representative histological sections of different groups are shown. A: sham group; B: cadmium-exposed group; C: FMT 0.5+Cd group; D: BUD 0.25+Cd
group; E: FMT 0.5+BUD 0.25+Cd group. All sections are stained with hematoxylin–eosin and shown at 6200. Arrows indicate inflammatory cell
infiltration into alveoli.
doi:10.1371/journal.pone.0109136.g003
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activity. No significant correlation between MMP-9 activity and
inflammatory markers measured in the present study was found in
rats pretreated with formoterol. However, the modulation of
MMP-9 activity was respectively correlated with neutrophil
(r = 0.54, P,0.05) and macrophage concentrations (r = 0.65, P,
0.01) in BALF when calculated with values obtained in cadmium
group, and in rats pretreated with budesonide. Similar correlation
was also detected for the severity of inflammatory infiltration
(r = 0.50, P,0.05) when budesonide was administrated. A
significant inhibitory effect on MMP-9 activity was observed in
rats pretreated with the combination of both drugs (Fig. 5B). As
illustrated in figure 6, this enhanced inhibitory effect on MMP-9
activity induced by combination of inefficient concentrations of
both drugs was directly correlated with neutrophil (r = 0.40, P,
0.05) and macrophage concentrations (r = 0.43, p,0.05) in BALF
and severity score of inflammation (r = 0.48, P,0.05) when
calculated with individual values obtained in cadmium group
and in rats pretreated with the low concentrations of formoterol
and budesonide alone and in combination (Fig. 6A–C).
Effects of formoterol and/or budesonide on cytokine and
chemokine levels in BALF
Cadmium exposure did not induce any significant variation in
IL-1b, TNF-a and IL-8 in BALF as compared to sham group (data
not shown).
Discussion
While being very potent anti-inflammatory drugs, GCs are also
known to be sometimes poorly active against neutrophilic
pulmonary inflammation as that occurring in COPD patients
especially during exacerbations [24]. The aim of this paper was to
investigate whether their activity can be enhanced when associated
with a LABA in rats exposed to a single inhalation of cadmium
through a down-regulation of MMP-9 which has been shown to
play a key role in this model [10].
Tobacco smoke being a main source of cadmium for non-
occupationally exposed population, active smokers are thus highly
exposed to this pollutant but passive smokers are also concerned as
confirmed by high indoor air concentrations due to environmental
tobacco smoke [2]. Occupationally exposed workers can also be
detected in industries using cadmium in their manufacturing
Figure 4. Inflammatory scores attributed to the severity (A, C) and extent (B, D) of histological injuries. For abbreviation meaning: see
Fig. 1 and Fig. 2 legend. * Indicates a significant difference in comparison with sham group (* P,0.05, ** P,0.01, *** P,0.001); # indicates a
significant difference in comparison with cadmium-exposed group (# P,0.05, ## P,0.01, ### P,0.001). 1 indicates a significant difference in
comparison with FMT 0.5+BUD 0.25+Cd group (1 P,0.05, 11 P,0.01).
doi:10.1371/journal.pone.0109136.g004
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process such as nickel-cadmium battery production, electronic
components, metallurgy and the majority of cadmium present in
atmosphere is the result of fossil fuel combustion and municipal
waste incineration [3]. Inhaled cadmium thus became a major risk
for public health. Environmental exposure to cadmium and blood
levels detected in exposed populations have been related with the
worsening FEV1% predicted values [8]. Several evidences also
suggest the involvement of cadmium in acute pulmonary
inflammation but also in OLD including COPD associated with
oxidative stress, chronic pulmonary inflammation and airspace
enlargements [5–8]. Despite the lack of precise information about
the particle size and concentration of cadmium inhaled by
animals, acute exposure of rats to cadmium can be considered
relevant to mimic some of the main features of the pathophysi-
ological changes during the exacerbations of this disease and to
investigate the influence of pharmacological agents.
Pulmonary deleterious effects induced by single or repeated
cadmium inhalation have been related with up-regulation of
various mediators and cytokines as GM-CSF, IL-6 [34,35]. MMPs
are also involved in air pollutants-induced pulmonary inflamma-
tion by acting on matrix remodeling and modulation of
inflammation and cell signaling [36]. Within the MMP family,
MMP-9 is suspected to play a predominant role in several murine
models of acute lung injury but also in patients with acute lung
inflammation [16,37–39]. Elevated expression of MMP-9 has been
observed in murine embryonic liver cells BNL CL2 stimulated by
cadmium as well as in dogs exposed to cadmium inhalation
leading to a marked neutrophilic inflammation [21,40]. Consistent
with these findings, MMP-9 has also been shown to be involved in
the model used in this study as previously demontsrated by the
anti-inflammatory effects provided by the inhibition of MMPs
activity [10,11]. Inflammatory cells including macrophages were
demonstrated to be a major source of MMP-9 as well as resident
cells [12,13,15,41] explaining why our study was focused on this
key enzyme showing an increased activity in response to acute
exposure to cadmium.
The two pharmacological compounds selected for this study are
very commonly used in human therapy as well the route of
administration. Ideally, the pharmacological effects of inhaled
drugs should be related to the drug concentrations in the lung
tissue or to the drug intake to construct dose-response curves.
However, inhalation of chemical compounds makes the exact
determination of these parameters in small rodents very difficult
[42]. The drug intake being unknown in our study, the amplitude
of the effects was related to the concentrations of the nebulized
solutions as performed in other studies [18,20,28,42]. In a previous
study, it was shown that the high concentration of formoterol
(1 mg/30 ml) we used in the present work was able to partially
protect the lungs against the bronchoconstrive effects of metacho-
line in healthy rats and to exert a protective effect against a single
dose cadmium-induced acute pulmonary inflammation [11]. The
lower concentration (0.5 mg/30 ml) of formoterol exerted a mild
bronchodilatory effect with slight or no protective effect against
cadmium-induced inflammation. Selection of these concentrations
in our study aimed to investigate relevant pharmacological
concentrations with likely no additional side effects. Budesonide
is a very potent anti-inflammatory agent in rats as demonstrated
by Birrell et al. [43] who reported a dose-related significant
inhibitory effects of budesonide, ranging 0.3–10 mg/kg and
administrated intratracheally, on the lipopolysaccharide (LPS)-
induced lung tissue neutrophilia and on a broad range of
inflammatory mediators such as MMP-9, TNF-a and IL-1b. An
optimal inhibition was already obtained at doses as low as 1 mg/
kg in this murine model of LPS-induced lung inflammation.
During preliminary dose titration assays, a range of concentrations
of budesonide has been evaluated. The two concentrations
(0.25 mg/15 ml and 0.5 mg/15 ml) selected to exert a low to
moderate effect in the present study were finally identical to those
of formoterol, considered as a not very powerful anti-inflammatory
agent. This likely reveals the low sensitivity of heavy metals-
induced pulmonary inflammation to GCs suggested by previous
studies in rats and dogs exposed to cadmium and to betamethsone
and prednisolone respectively [20,21].
The ability of GCs to modulate the protease/anti-protease
balance in the lungs seems to markedly influence their efficacy and
may vary depending on the causal factors of pulmonary
Figure 5. Effects of formoterol and/or budesonide on MMP-9
gelatinolytic activity in BALF. For abbreviation meaning: see Fig. 1
and Fig. 2 legend. * Indicates a significant difference in comparison
with sham group (* P,0.05, ** P,0.01, *** P,0.001); # indicates a
significant difference in comparison with cadmium-exposed group (#
P,0.05, ## P,0.01). 1 indicates a significant difference in comparison
with FMT 0.5+BUD 0.25+Cd group (1 P,0.05, 11 P,0.01).
doi:10.1371/journal.pone.0109136.g005
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inflammation. The suppression of elevated MMP-2 and MMP-9
levels by GCs associated with their anti-inflammatory action has
been reported in both animal models of acute lung injury and in
inflammatory cells stimulated respectively by LPS and H2O2
[22,31,44,45]. By contrast, dexamethasone exerted no action on
MMP-9 release by blood neutrophils stimulated with N-formyl-
methionyl-leucyl-phenyl-alanine (fMLP) [19] and fluticasone failed
to decrease the release of MMP-9 and MMP-2 by human
neutrophils stimulated with cigarette smoke medium known to
lead to refractory inflammation in COPD patients [30]. In the
same way, the inability of betamethasone to rebalance MMP-2-9/
TIMP-1-2 ratio has been related to its inability to prevent the
development of pulmonary emphysema associated to cadmium
inhalation for 5 weeks [20] and a similar mechanism has been
described in dogs [21].
It can thus be hypothesized (i) that a limited down-regulating
effect on MMPs activity could thus contribute to limit the anti-
inflammatory effects of GCs and (ii) that any drugs able to restore
their action on MMPs activity would contribute to restore their
anti-inflammatory effects. Our data provide additional convincing
arguments in favour of this first hypothesis. Indeed, the protective
effect against the cadmium-induced lung injuries only occured
with the high concentration of budesonide able to inhibit the
activity of MMP-9 and strong correlations between the inflam-
matory markers measured in the present study and MMP-9
activity calculated taking into account the budesonide groups were
obtained. The fact that a mild anti-inflammatory effect can be
induced by the low concentration of budesonide without
significant influence on MMP-9 activity suggests that other
mechanisms of action might be involved. The second hypothesis
is supported by data provided by formoterol and budesonide
combination. The pulmonary anti-inflammatory effects of b2-
adrenoceptor agonists have been recently reviewed [25]. Briefly,
these drugs can inhibit the inflammatory cell adhesion, the
activation and the release of inflammatory mediators in various
models of acute and chronic inflammation [46]. The influence of
LABAs on pulmonary MMPs activity and expression related to
pulmonary inflammation remains controversial. In contrast to the
finding of Mortaz et al. [30] who found no influence of salmeterol
on the release of elastase, MMP-2 and MMP-9 from human
neutrophils stimulated with cigarette smoke, our previous studies
provided evidences that inhibitory effects of formoterol on
increased MMP-9 activity in BALF sampled in rats with acute
and chronic pulmonary inflammation can be associated to a
significant protective effect [11,12]. The absence of correlation
between MMP-9 activity and inflammatory markers in rats
pretreated with formoterol in the present study can be explained
by the more limited concentrations of formoterol than that tested
previously ranging 1 mg/30 ml to 4 mg/30 ml. Taking into
account these previous data, significant correlations between
MMP-9 activity and neutrophil (r = 0.40, P,0.05) and macro-
phage (r = 0.5, P,0.01) concentrations in BALF as well as severity
score of inflammatory injuries (r = 0.59, P,0.01) were detected.
To check whether LABA can improve the protective effects of
GCs in this relatively refractory experimental model, ineffective
concentrations of budesonide and formoterol were combined
Figure 6. Linear correlation between MMP-9 activity with inflammatory cell counts and severity score of inflammatory injuries. The
relationship between individual values of MMP-9 activity and the different inflammatory parameters obtained in cadmium group and in rats
pretreated with low concentrations of formoterol and/or budesonide is represented. Coefficient of correlation is indicated for each figure.
doi:10.1371/journal.pone.0109136.g006
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before the cadmium inhalation. While the decrease in macrophage
count in BALF was not significant, this combination exerted a
significant and potentiated action on MMP-9 activity leading to a
marked protective effect against pulmonary neutrophilic inflam-
mation and lung injuries. The significant correlations between
MMP-9 activity and inflammatory parameters calculated taking
into account the animals treated with a combination of both drugs
also argue in favor of this mechanism. The model used in the
present study does not allow to determine whether the inhibited
MMP-9 activity in BAL was the result of a direct action on
producing cells or to an indirect action through a decrease in their
number. As the major source of MMP-9 in this model being the
macrophages which number remains unchanged, this last
hypothesis seems unlikely.
In conclusion, high concentrations of inhaled formoterol or
budesonide protect the lungs against the cadmium-induced acute
neutrophilic inflammation by reducing the parenchyma inflam-
matory infiltration of neutrophils. The reduced MMP-9 activity
recorded upon the action of both drugs could contribute to this
protective effect. Due to the limited action of both drugs in this
model, lower concentrations of both drugs exert no or few anti-
inflammatory effects. This lack of protective effects has been
related to the absence of action on MMP-9 activity. When
ineffective concentrations of both compounds are combined, the
interaction of both drugs provides an enhanced protection against
the cadmium-induced lung injuries likely through a down
regulation of MMP-9 activity. The finding of this present study
showing the potentiation of interaction between both drugs at low
inefficient concentrations could provide a new therapeutic strategy
for restoring GC sensitivity so as to well control heavy metals-
induced pulmonary inflammation with a less additional side
effects.
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